Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 38, 2013, Pages 15407-15412

  Grigg, Patricia ^a   Titong, Allison ^b   Jones, Leslie A ^a   Yilma, Tilahun D ^a,c   Verardi, Paulo H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GAMMA INTERFERON; TETRACYCLINE; VIRUS VECTOR; DRUG CARRIER; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPRESSOR GENE; VACCINIA VIRUS; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; CELL LINE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM; PATIENT SAFETY; SCID MOUSE; STANDARDS;

ANIMALIA; MUS; REPLICATION COMPETENT VIRUSES; VACCINIA VIRUS;

ANIMALS; CELL LINE; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; PATIENT SAFETY; PROMOTER REGIONS, GENETIC; TETRACYCLINE; VACCINES; VACCINIA VIRUS;

EID: 84884344225     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314483110     Document Type: Article

References (37)

1. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M (2013) Viral vectors: A look back and ahead on gene transfer technology. New Microbiol 36(1):1-22.
2. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8(1):62-73.
3. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7): 658-670.
4. Verardi PH, Titong A, Hagen CJ (2012) A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication. Hum Vaccin Immunother 8(7): 961-970.
5. Fenner F, Henderson DA, Arita I, Jeek Z, Ladnyi ID (1988) Smallpox and Its Eradication (World Health Organization, Geneva, Switzerland), p 1460.
6. Henderson DA, et al.; Working Group on Civilian Biodefense (1999) Smallpox as a biological weapon: Medical and public health management. JAMA 281(22):2127-2137.
7. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA (2003) Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37(2):251-271.
8. Casey CG, et al. (2005) Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294(21):2734-2743.
9. Lane JM, Goldstein J (2003) Adverse events occurring after smallpox vaccination. Semin Pediatr Infect Dis 14(3):189-195.
10. Kemper AR, Davis MM, Freed GL (2002) Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 5(2):84-90.
11. Lane JM, Goldstein J (2003) Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med 138(6):488-493.
12. Traktman P, et al. (2000) Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: Construction and characterization of a tetracyclineinducible recombinant. J Virol 74(8):3682-3695.
13. Giavedoni LD, et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci USA 89(8):3409-3413.
14. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA (1990) Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 20(1):157-161.
15. Legrand FA, et al. (2005) Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci USA 102(8):2940-2945.
16. Papin JF, et al. (2011) Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci USA 108(36):14926-14931.
17. Punjabi A, Traktman P (2005) Cell biological and functional characterization of the vaccinia virus F10 kinase: Implications for the mechanism of virion morphogenesis. J Virol 79(4):2171-2190.
18. Unger B, Traktman P (2004) Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions. J Virol 78(16):8885-8901.
19. Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23(6):1094-1097.
20. Bertholet C, Drillien R, Wittek R (1985) One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc Natl Acad Sci USA 82(7):2096-2100.
21. Hillen W, Berens C (1994) Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu Rev Microbiol 48:345-369.
22. Kleinschmidt C, Tovar K, Hillen W (1991) Computer simulations and experimental studies of gel mobility patterns for weak and strong non-cooperative protein binding to two targets on the same DNA: Application to binding of tet repressor variants to multiple and single tet operator sites. Nucleic Acids Res 19(5):1021-1028.
23. Yao F, et al. (1998) Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 9(13):1939-1950.
24. Cawthorne C, Swindell R, Stratford IJ, Dive C, Welman A (2007) Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. J Biomol Tech 18(2):120-123.
25. Centlivre M, et al. (2010) Autoregulatory lentiviral vectors allow multiple cycles of doxycycline-inducible gene expression in human hematopoietic cells in vivo. Gene Ther 17(1):14-25.
26. Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: A novel multimechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64-71.
27. Flexner C, Hügin A, Moss B (1987) Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330(6145):259-262.
28. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE (1987) Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329(6139): 545-546.
29. De Clercq E (2010) Historical perspectives in the development of antiviral agents against poxviruses. Viruses 2(6):1322-1339.
30. Miller CH, Maher SG, Young HA (2009) Clinical use of interferon-gamma. Ann N Y Acad Sci 1182:69-79.
31. Cao JX, Upton C (1997) gpt-gus fusion gene for selection and marker in recombinant poxviruses. Biotechniques 22(2):276-278.
32. Hammond JM, Oke PG, Coupar BE (1997) A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods 66(1):135-138.
33. Hwang SR, Garza CZ, Wegrzyn JL, Hook VY (2005) Demonstration of GTG as an alternative initiation codon for the serpin endopin 2B-2. Biochem Biophys Res Commun 327(3):837-844.
34. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD (2001) Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 75(1):11-18.
35. Rubinstein S, Familletti PC, Pestka S (1981) Convenient assay for interferons. J Virol 37(2):755-758.
36. Hojman P, Eriksen J, Gehl J (2007) Tet-On induction with doxycycline after gene transfer in mice: Sweetening of drinking water is not a good idea. Anim Biotechnol 18(3):183-188.
37. Honnorat-Benabbou VC, Lebugle AA, Sallek B, Duffaut-Lagarrigue D (2001) Stability study of tetracyclines with respect to their use in slow-release systems. J Mater Sci Mater Med 12(2):107-110.